These measures are designed to prevent misuse, ensure compliance with our policies, and support the safe and appropriate use of our platform
Tirzepatide (dual GLP-1/GIP receptor agonist): In the SURMOUNT-1 trial, participants on the highest tirzepatide dose (15 mg) achieved approximately 22.5% body weight reduction at 72 weeks
Online semaglutide prescription reviewed by a licensed physician
The principle applies equally to all injectable peptides
Glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) levels in the sera increased after WSCA administration Despite unchanged receptor expression, serum GLP-1 and PYY levels in db/m and db/db mice in the WSCA group were significantly higher than those in the control group after eight weeks of administration
If you or a loved one is prescribed a GLP-1 agonist, well schedule regular follow-up visits to assess your progress, check for side effects, and make sure the medication is still right for you